BioSpace News Archive

Harbour BioMed today announced that the results of its phase Ib clinical trial of porustobart (HBM4003) in combination of toripalimab in patients with advanced high-grade neuroendocrine neoplasms.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will present updated data from the Phase 1 study evaluating the safety and efficacy of once-weekly selinexor in combination with ruxolitinib in patients with treatment-naïve myelofibrosis (NCT04562389) at the American Association for Cancer Research (AACR) Annual Meeting 2023.

Oxford Nanopore Technologies plc (LSE: ONT) (“Oxford Nanopore”) and bioMérieux SA today announced that they have teamed up to improve health outcomes globally by exploring selected opportunities to bring nanopore sequencing to the infectious disease diagnostics market.

Flamingo Therapeutics (“Flamingo”) today announced a presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida.

Rapid Dose Therapeutics Corp., a Canadian biotechnology company leveraging an innovative, proprietary oral delivery platform, is announcing changes to its board of directors.

Aadi Bioscience, Inc. (NASDAQ: AADI) today announced the presentation of three posters at the 2023 American Association for Cancer Research Annual Meeting (AACR), taking place April 14-19, 2023, in Orlando, FL.

CMML is an aggressive, poorly understood cancer; approximately 20% of patients survive three years from diagnosis

HOOKIPA Pharma Inc. announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-statutory options to a new employee to purchase an aggregate of 50,000 shares of the Company’s Common Stock under HOOKIPA’s 2023 Inducement Plan.

PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes, announced it has received a letter from the Listing Qualifications staff of The Nasdaq Stock Market notifying the Company that it is no longer in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Global Market.

InflaRx N.V. announced that it has completed its underwritten public offering of 9,411,765 ordinary shares at a public offering price of $4.25 per ordinary share.